Quote: And I do agree that we should treat them formally
Quote: And I do agree that we should treat them formally with professional courtesy.
Is professional courtesy an open season on the FDA from 43,000 Cytodyn investors?
If only if the FDA would post or publish a retraction of their comment of “ No Benefit “ that would at least set the story straight and remove harm that was laid on CytoDyn internationally since we chose to take a new international path for our immediate use and possible approvals.
The FDA has to realize that they have harmed our chances everywhere in the world. This is why I believe the stock holders should have left the FDA alone in the first place and should only try to get a middle person representing us stock holders like a elected official or someone similar.
The continued assault by who knows how many of the 43,000 investors directed at the FDA might of been the reason for the letter in the first place. We can’t discount that right now. We have essentially or quite possibly been the reason we are in this position. How many investors wrote very derogatory letters and cussed them out? Shooting ourself in the foot is not the position I like to be in. Not only do we NOT have an FDA EUA but it has probably delayed our chances internationally at one and will make us prove our molecule in trials before an international or equivalent EUA in any country. Time is our injury. Cost of trials might cost us more dilution. I hate the thought of more dilution personally.
Did we screw ourselves or just delay our chances? I would think it will be on trial size that shows how much time we might of cost ourselves. Sometimes poking the bear is better served by another equally important bear like a Senator with the likes of Bernie Sanders. Someone with pull and standing that demands answers. Not an assault by thousands of investors. An all out assault by our stock holders didn’t help us is what I believe. If it continues and is ongoing... what else will we screw ourselves out of? Another possible EUA for LH’s or a BTD for Cancer? How much do we need to lose before we learn the most expensive lessons when we can’t get any approvals in the USA? Where does it stop? How much pressure is really needed by a peanut gallery of stock holders?
All I can really say... If you must be active... don’t focus on the FDA but elected officials to fight for us. Be smart in your activism. Don’t be direct by the thousands at the FDA. Know that there is 43,000 investors and the FDA will hate us for our all out assault as activists. Just please be smart!
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Sneak Peek into Yuhang's Technological Leap Imagine strolling through a place where technology and nature coexist in harmony. That's exactly what journalists from around the globe got to experience during their recent jaunt to Yuhang District in Hangzhou. We're talking about reps from South Korea, Turkey, the U.S., and even Cuba getting a firsthand look at Yuhang's...
Continue Reading
Breaking the Mold on Renting Approvals in Michigan Over in Ann Arbor, Michigan, the rental market ain't all sunshine and roses for folks trying to snag a place to live. The vacancies are unusually high—a whopping 8.9%—yet people are still being turned away. Why? Because rigid credit scores are tossing deserving renters aside like yesterday's news. Now, here comes...
Continue Reading
Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...
Continue Reading
A Deep Dive into the Prayers of Apostle Paul Gary P. Rohrmayer's latest devotional takes believers on a unique journey, exploring the Apostle Paul's prayers across his missionary paths. But don't expect just another preacher prophesying from the pulpit. This is more like peeling back layers of history, bit by bit. 28 Days of Spiritual Insights Each day within the book...
Continue Reading
Holiday Heatwave Meets Winter Cheer with Martin's Rolls Hold onto your oven mitts, folks, because Martin’s Famous Potato Rolls and Bread is stirring up the winter doldrums with an unexpected twist this holiday season. Forget the old cranberry sauce routine—it’s all about mixing sunny vibes with frosty festivities in their "Very Merry Martin’s: Holiday Heatwave."...
Continue Reading
Unveiling the Future at ADIPEC 2026 ADIPEC 2026 kicked off with the kind of fanfare you'd expect only from a heavyweight gathering at the intersection of energy, AI, and investment strategy. Dr. Sultan Al Jaber and Sam Altman, two bigwigs in their fields, stood front and center to point out the latest priorities shaping these industries. And let me tell you, it's a wild...
Continue Reading
ADC Therapeutics: Eyes on the Financial Prize So here we are, folks—ADC Therapeutics is blitzing the stage and gearing up to spill the beans on their third-quarter saga come November 9, 2026. Who needs a crystal ball when you've got a press release to dissect every number and nuance? Anticipating the Numbers: What's at Stake? ADC Therapeutics has been riding the wave of...
Continue Reading
Zensar's Q2 Performance: Growth Amid Shifting Sands Is Zensar Technologies quietly carving a spot for itself in the cutthroat tech marketplace, or are we just seeing a temporary glimmer during a complex market scenario? With a constant currency growth rate of 4.1% in Q2FY27, Zensar sure seems to have gotten something right. But does this mean they’ve got the long-term...
Continue Reading
Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....
Continue Reading
Rough Times for Fluence Energy Shareholders Fluence Energy, Inc. (NASDAQ:FLNC) has been treading choppy waters with a stock plunge of 34.63%, leaving investors gasping for air. This isn't your typical market jitters—it's tied up with a securities fraud class action, which seems to have taken the wind right out of their sails. In the twisted world of energy stocks, any...
Continue Reading
Top 5 Most Recently Viewed Articles
Great Southern Bancorp Initiates Fourth Quarter Dividend Great Southern Bancorp, Inc. (NASDAQ: GSBC) has recently declared a quarterly dividend of $0.40 per common share for its shareholders. This announcement comes as part of the company's ongoing commitment to providing excellent returns to its stockholders. History of Reliable Dividend Payments This latest dividend...
Continue Reading
Chevrolet Bolt EV Affordable Pricing and Features General Motors Co. (NYSE: GM) has recently introduced its most affordable electric vehicle, the Chevrolet Bolt EV, with an eye-catching starting price of $29,000. This new model features significant upgrades including a refreshed battery and technologically advanced capabilities that aim to enhance the EV driving...
Continue Reading
Overview of the Growing Server Market The server market is on the verge of a significant transformation, projected to reach an impressive USD 198.81 billion by the end of the forecast period. This translates to a remarkable compound annual growth rate (CAGR) of 9.3% from 2024 to 2031. Such exponential growth can largely be attributed to the rising demand for efficient...
Continue Reading
United Methodist Communities Foundation Hosts Annual Fundraiser The United Methodist Communities Foundation (UMC Foundation) is gearing up for its much-anticipated annual fundraising event titled "United Together: A Celebration of Innovation." This event showcases the foundation's unwavering dedication to advancing innovation in the senior care sector. A Virtual...
Continue Reading
NeoSystems and SNC Forge Strategic Partnership NeoSystems and SNC Defensible Security have come together to create a strong alliance aimed at providing essential services for IT management and cybersecurity tailored for defense contractors. This collaboration is designed to address the growing need for comprehensive cybersecurity solutions in light of the Department of...
Continue Reading